Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average) (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $63355.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.21% to $63355.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $63355.0, a 2.21% increase, with the full-year FY2025 number at $63355.0, up 2.21% from a year prior.
  • Shares Outstanding (Weighted Average) was $63355.0 for Q4 2025 at Fulcrum Therapeutics, down from $62.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $62.6 million in Q3 2025 to a low of $32076.0 in Q2 2021.
  • A 5-year average of $26.4 million and a median of $62669.5 in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 99.87% in 2022, then skyrocketed 148503.57% in 2023.
  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average) stood at $35361.0 in 2021, then grew by 27.23% to $44991.0 in 2022, then soared by 36.27% to $61310.0 in 2023, then rose by 1.1% to $61984.0 in 2024, then increased by 2.21% to $63355.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Shares Outstanding (Weighted Average) are $63355.0 (Q4 2025), $62.6 million (Q3 2025), and $62.5 million (Q2 2025).